Estradiol action in atherosclerosis and reendothelialization

Area of Science:

• Cardiovascular Science
• Immunology
• Endocrinology

Background:

• Hormone replacement therapy (HRT) in postmenopausal women is linked to increased coronary artery disease risk.
• Epidemiological and experimental studies suggest estradiol (E2) has significant atheroprotective effects, particularly in premenopausal women and animal models.

Purpose of the Study:

• To elucidate the complex, dual effects of estrogens on cardiovascular health.
• To understand the role of the endothelium-immune system interaction in E2's atheroprotective actions.
• To identify mechanisms underlying E2's beneficial effects on arteries for improved cardiovascular disease prevention.

Main Methods:

• Investigation of E2's effects in mice deficient in T and B lymphocytes.
• In vitro studies on cultured cells and in vivo studies on animal models.
• Analysis of E2's impact on endothelial nitric oxide (NO) and prostacyclin production.
• Assessment of E2's mediation via estrogen receptor alpha (ERα) versus estrogen receptor beta (ERβ).

Main Results:

• E2's atheroprotective effect is dependent on mature T and B lymphocytes, highlighting the endothelium/immune system interplay.
• E2 exhibits both anti-inflammatory effects in vitro and pro-inflammatory effects in vivo on specific immune cells.
• E2 enhances endothelial prostacyclin production and accelerates endothelial regrowth, promoting vascular healing.
• Most E2 effects are mediated by ERα, independent of ERβ.

Conclusions:

• Estrogen's cardiovascular effects are complex, involving both beneficial (prostacyclin-mediated) and potentially detrimental (in vivo pro-inflammatory) actions.
• The endothelium and immunoinflammatory system are critical targets for E2's vascular effects.
• Further research and mouse models are essential for developing selective estrogen receptor modulators (SERMs) for cardiovascular disease prevention after menopause.